

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA ISOTOPE & RADIATION CORPORATION

中國同輻股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1763)

VOLUNTARY ANNOUNCEMENT RADIOACTIVE SOURCE R&D AND PRODUCTION BASE (PHASE II) SUCCESSFULLY GRANTED RADIATION SAFETY PERMIT, MARKING THE FULL COMPLETION AND COMMISSIONING OF ASIA'S LARGEST RADIOACTIVE SOURCE R&D AND PRODUCTION BASE

This announcement is made by China Isotope & Radiation Corporation (“**China Isotope & Radiation**” or the “**Company**”) on a voluntary basis to keep the shareholders and potential investors informed of the latest business development of the Company.

The board of directors of the Company is pleased to announce that, recently, the radioactive source R&D and production base project (Phase II) of Chengdu Gaotong Isotope Co., Ltd. (CNNC) (成都中核高通同位素股份有限公司), a subsidiary of China Isotope & Radiation, was completed and successfully approved for the addition of licensed items to its radiation safety permit. The production lines for radioactive sources such as Californium-252, Caesium-137 and Americium-241 have officially commenced production, fully meeting the diversified needs of the market.

In August 2025, Phase I of the radioactive source R&D and production base project received the radiation safety permit. The granting of the radiation safety permit for licensed items for Phase II marks the full completion and commencement of production of the largest radioactive source R&D and production base in Asia. The base has 14 radioactive source production lines, including for Carbon-14 sources and Krypton-85 sources, and is capable of producing high-quality radioactive source products of over 70 types of nuclides. The annual production capacity of radioactive sources will exceed 100,000 units, meeting the current demand for radioactive sources in fields such as industry, agriculture, medicine, national defense and aerospace in China.

The full commencement of production of this project marks the accelerated realization of technical upgrades and the transition from old to new production capacity in the field of sealed radioactive sources in China, consolidating China's leading position in the research and development and industrial application of radioactive sources. Meanwhile, with the release of production capacity, relevant products will not only satisfy domestic demand but also continue to intensify international market expansion efforts, actively serving countries along the "Belt and Road".

By Order of the Board
China Isotope & Radiation Corporation
Xiao Yafei
Chairman

Beijing, the PRC, 10 June 2026

As at the date of this announcement, the Board comprises Mr. Xiao Yafei, Mr. Zhang Junqi, Ms. Huo Yingying as executive Directors; Mr. Chen Zan, Mr. Ding Jianmin and Ms. Chang Jinyu as non-executive Directors; and Mr. Poon Chiu Kwok, Ms. Chen Jingshan, Mr. Lu Chuang and Mr. An Rui as independent non-executive Directors.